Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 22;7:12191. doi: 10.1038/s41598-017-12368-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Clinical seizure types occurring at 2, 3, 4, and 6 weeks following intrahippocampal kainate injection in mice and effect of treatment with a combination of NBQX and ifenprodil during the latent period of this model. Data are combined from experiments 2 and 3 (see Fig. 1). In each graph, the number of clinical seizures in individual mice is shown; the group median is indicated by the horizontal line. Seizures are differentiated into focal (stage I-III) and generalized (stage IV and V) seizures. Analysis of data by two-way ANOVA indicated a significant difference between vehicle and drug treated groups (P = 0.0381); post hoc analysis by Dunn’s multiple comparisons test indicated that drug treatment significantly reduced seizure frequency at 2 weeks after kainate (P = 0.0051).